Posted by Michael Wonder on 26 Nov 2020
Lynparza (olaparib) receives Health Canada approval for the treatment of BRCA or ATM gene-mutated metastatic castration-resistant prostate cancer
25 November 2020 - On 21 August 2020, Health Canada approved Lynparza (olaparib), for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM-mutated metastatic castration-resistant prostate cancer who have progressed following prior treatment with a new hormonal agent. BRCA1/2 or ATM gene mutation must be confirmed before Lynparza treatment is initiated.
The Health Canada approval of Lynparza for BRCA or ATM gene-mutated metastatic castration-resistant prostate cancer was based on data from Cohort A of the global Phase 3 PROfound trial.
